Loading company…
Riskpilot
← Back to search
Sign in
Get full access
ZEMA Pharma Consulting ApS
APS
Active
CVR 42680427
Hjemmevej 42
Business and other management consultancy activities · NACE 7020
Est. 2021
1 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2025
DKK 102K
-22% vs 2024
EBITDA margin
-240.8%
+37% vs 2024
Equity ratio
44.9%
Financial strength
Net profit 2025
DKK -217K
+23% vs 2024
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
1M
2022
1M
0%
2023
0M
-100%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
DKK 102K
-22%
EBITDA
DKK -246K
+37%
Net profit
DKK -217K
+23%
Total assets
DKK 789K
+25%
Equity
DKK 355K
-38%
Employees
1
—
Company information
Legal name
ZEMA Pharma Consulting ApS
CVR number
42680427
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
15. september 2021
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Contact
Address
Hjemmevej 42
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Business and other management consultancy activities
Companies in Gentofte
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
1M
2022
1M
2023
0M
2024
0M
2025
EBITDA
DKK millions
0M
0M
1M
1M
1M
1M
2022
1M
2023
0M
2024
0M
2025
Income statement
DKK thousands
Item
2022
2023
2024
2025
Revenue
1.146
1.472
131
102
Staff expenses
-44
-501
-520
-348
EBITDA
1.102
971
-389
-246
Depreciation & amort.
-0
-0
-0
-0
EBIT
1.102
971
-389
-246
Net financials
-89
71
108
29
Profit before tax
1.013
1.041
-282
-217
Tax
223
229
-0
-0
Net profit
790
812
-282
-217
Balance sheet
DKK thousands
Item
2022
2023
2024
2025
Total assets
1.187
1.587
633
789
Equity
830
853
571
355
Long-term debt
0
0
0
0
Short-term debt
358
734
61
434
Total debt
358
734
61
434
Financial ratios
5-year trend
EBITDA margin
-240.8%
This company
15.8%
Market median
-1624% vs market
2022
2025
Equity ratio
44.9%
This company
38.2%
Market median
+18% vs market
2022
2025
Return on equity
-61.1%
This company
18.4%
Market median
-432% vs market
2022
2025
Net profit margin
-212.0%
This company
8.1%
Market median
-2717% vs market
2022
2025
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
2022
2025
Debt / equity
1.23×
This company
0.62×
Market median
-98% vs market
2022
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-09-15 – 2022-09-30
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Mads Torkild Hansen
Individual
100.0%
100.0%
2021
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of ZEMA Pharma Consulting ApS also hold positions in
0
other companies.
Person
Role here
Other companies